Version 1 du 22 avril 2020
Combination of hydroxychloroquine plus azithromycin as potential treatment for COVID 19 patients: pharmacology, safety profile, drug interactions and management of toxicity.
Guillaume Hache, Jean Marc Rolain, Philippe Gautret, JeanClaude Deharo, Philippe Brouqui, Didier Raoult, Stéphane Honoré
The coronavirus disease COVID-19, caused by infection with SARS-CoV2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to- or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rational of this combination, and to provide safety information in order to prevent toxicity and drug-drug interactions, based on available evidence.